Project Grant R01CA289378
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$378K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to develop ultra-potent, pharmacologically stable synthetic transcriptional repressors (STRs) that can directly target and inhibit the oncogenic activities of the stress-induced transcription factors XBP1 and HIF1A in triple-negative breast cancer (TNBC). The $667,792 award, effective from June 1, 2024 to May 31, 2029, will fund research at the...
The National Cancer Institute (NCI) awarded a $1,217,906 Project Grant under the Cancer Biology Research (CFDA 93.396) federal grant program to Cosmyc Inc. in Dover, DE. The award, with a project period from June 2024 to May 2025, will support research aimed at understanding the fundamental biological mechanisms underlying cancer development, progression, and potential treatment interventions, with a focus on the inhibition of MYC:TRRAP interaction in cancer. The research is expected to...
The National Cancer Institute (NCI) awarded a $431,968 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Baylor College of Medicine. The grant, with a performance period from August 15, 2024 to July 31, 2029, will fund research to elucidate how the oncogenic MYCN gene drives metabolic reprogramming in high-risk neuroblastoma, leading to an immunosuppressive tumor microenvironment. The researchers aim to modulate the metabolic environment of neuroblastoma tumors to...
This $452,549 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by Emory University to comprehensively characterize the intrinsic molecular features and extrinsic tumor microenvironment of MYC-driven osteosarcoma. The key objectives are to: Identify the cross-species molecular signatures and cell-cell communications in MYC-hyperactivated human and murine osteosarcoma tumors. This will involve profiling intrinsic and...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides funding to Baylor College of Medicine to investigate how the oncogene MYCN drives an immune-suppressive tumor microenvironment in neuroblastoma. The $225,101 award, running from April 2025 to March 2027, aims to (1) determine how MYCN rewires T cell metabolism to drive immune suppression, and (2) elucidate how MYCN-induced lipogenesis contributes to a suppressive...
The National Cancer Institute (NCI) awarded a $661,072 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Northwestern University to develop a novel therapy with dual immuno-oncology targeting capabilities for the treatment of triple negative breast cancer. The project aims to conduct IND-enabling studies for a first-in-class USP22-specific small molecule inhibitor that can impair cancer cell growth, stemness, and boost anti-tumor immunity. This research aligns with the NCI's goals to...
The National Cancer Institute (NCI) awarded Transcode Therapeutics, Inc. a $1,011,207 Project Grant (CFDA 93.395 - Cancer Treatment Research) to support Phase I clinical testing of a novel therapeutic agent, MN-anti-miR10b, for the treatment of metastatic cancer. This first-in-class therapy targets miRNA-10b, a validated driver of metastasis in numerous preclinical and clinical studies. Preclinical data has shown that MN-anti-miR10b can mediate significant miR-10b inhibition in vivo, leading...
This federal Project Grant award of $230,010 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to investigate the underlying mechanisms driving the aggressive metastasis of small cell lung cancer (SCLC). The project utilizes innovative methods including human pluripotent stem cell-derived pulmonary neuroendocrine cells, clinical samples, patient-derived xenografts, and advanced technologies such as single-cell sequencing and...
The National Cancer Institute (NCI) awarded a 5-year, $590,625 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of California, Davis to develop a novel therapeutic strategy targeting mutant p53, a tumor suppressor gene that is mutated in over half of human cancers. The key goals are to: Determine how mutant p53 expression is regulated by the CDK4/6-RBM38-eIF4G axis and the role of mutant p53 as a target of CDK4/6 inhibitors to suppress mutant p53-expressing triple...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $268,590 to The Johns Hopkins University to conduct research on the effects of MYC gene overexpression on protein translation dynamics and ribosome collisions in cancer cells. The key objectives are to investigate how MYC expression impacts protein synthesis, assess how it affects ribosome collision frequency and sensitivity to translation stress, and determine if...